Welcome to our dedicated page for PRF Technologies Ltd. SEC filings (Ticker: PRFX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PainReform Ltd. (PRFX) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. PainReform files Form 6-K current reports that furnish press releases, transaction details, financial statements, and other information under the Securities Exchange Act of 1934. These filings document key developments in both its specialty pharmaceutical programs and its DeepSolar energy analytics activities.
Recent 6-K reports include disclosures about PainReform’s majority investment in LayerBio Inc., the company behind the OcuRing™-K sustained-release ocular platform for cataract surgery, along with unaudited pro forma condensed combined financial information and LayerBio’s audited and unaudited financial statements. Other 6-Ks furnish press releases on topics such as acceptance of DeepSolar into the NVIDIA Connect program, the launch of Smart TDD for solar technical due diligence, and the advancement of DeepSolar’s automated reporting engine and DeepSolar Predict forecasting solution.
Filings also cover financial updates, including unaudited condensed financial statements and operating and financial reviews for interim periods, as well as corporate governance matters such as notices and proxy statements for the Annual General Meeting of Shareholders and changes in board composition. Together, these documents form an official record of PainReform’s clinical, commercial, and corporate progress.
On Stock Titan, investors can review these SEC submissions alongside AI-powered summaries that explain the significance of each report. Real-time updates from EDGAR help users follow new Form 6-K filings as they appear, while structured access to exhibits and financial data supports deeper analysis of PainReform’s pharmaceutical pipeline, LayerBio acquisition, and DeepSolar initiatives.
PainReform Ltd. (PRFX) filed a Form 6-K noting it issued a press release on November 5, 2025 titled “PainReform’s DeepSolar, Developing ‘DeepSolar Predict’ within the NVIDIA Connect Program, Featured in The Market Link’s ‘Watchlist Interview’ and Announces Progress Toward Pilot Projects.” The press release is attached as Exhibit 99.1 and incorporated by reference.
The report is signed by Ehud Geller, Executive Chairman of the Board and Interim Chief Executive Officer.
PainReform Ltd. filed a Form 6-K reporting that on October 1, 2025 it issued a press release announcing its financial results for the six months ended June 30, 2025 and furnished unaudited condensed financial statements and an operating and financial review for that period.
The filing also discloses a board change: Professor Eli Hazum resigned effective September 30, 2025 for personal reasons, expressly not due to any disagreement with management, and Asaf Shavit was appointed to the Board effective immediately; Mr. Shavit is a Certified Public Accountant with 35+ years of audit, tax and financial advisory experience.
PainReform Ltd., an Israel-based company, submitted a Form 6-K as a foreign private issuer. The report notes that on August 19, 2025, the company issued a press release titled “PainReform/DeepSolar Accepted into NVIDIA Connect Program.” The press release is furnished as Exhibit 99.1.
The filing is informational, formally placing this collaboration-related announcement into the company’s official U.S. disclosure record. No financial figures, deal terms, or operational metrics are included in this excerpt.
PainReform Ltd. completed a strategic investment in LayerBio to enter the global cataract surgery market, described in the filing as a $9 billion opportunity, via a non-opiate, non-steroidal postoperative NSAID drug delivery system. The report attaches the press release as Exhibit 99.1 and states the first paragraph of that release is incorporated by reference into the company’s Form S-8 and Form F-3 registration statements.
The filing is a disclosure of the investment and the attached press release; it does not provide financial terms, clinical data, or operational results within the text of the Form 6-K itself.